Repligen
RGEN · NASDAQ
$178.88+$2.45 (+1.39%)TodayMarket closed ·
Prev close $176.43
EPS: actual vs estimate
Beat the estimate in 7 of the last 8 quarters, by 14.1% on average
Next report: , before the market opens
- Quarter
- Q3 FY26
- EPS estimate
- $0.46
- Revenue estimate
- $206.73M
Reported EPS
Estimated EPS
| Quarter | Estimate | Reported | Surprise |
|---|---|---|---|
| Q2 FY26 | $0.4576 | $0.54 | +18.0% |
| Q1 FY26 | $0.3938 | $0.48 | +21.9% |
| Q4 FY25 | $0.4485 | $0.49 | +9.3% |
| Q3 FY25 | $0.4268 | $0.46 | +7.8% |
| Q2 FY25 | $0.3971 | $0.37 | −6.8% |
| Q1 FY25 | $0.3522 | $0.39 | +10.7% |
| Q4 FY24 | $0.4182 | $0.44 | +5.2% |
| Q3 FY24 | $0.3416 | $0.43 | +25.9% |
Earnings calls
- Wells Fargo 21st Annual Healthcare Conference
- RGEN - Earnings call Q2 2026
- BioLife Solutions, Inc., Repligen Corporation - M&A Call
- 46th Annual William Blair Growth Stock Conference
- Bank of America Global Healthcare Conference 2026
- RGEN - Earnings call Q1 2026
- 2026 KeyBanc Capital Markets Healthcare Virtual Forum
- Leerink Global Healthcare Conference 2026
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.